Investor News

Hyperfine Announces Appointment of Alok Gupta as Chief Financial Officer

August 23, 2021

“We are honored to welcome Alok Gupta to the Hyperfine senior leadership team,” said Hyperfine president and chief executive officer Dave Scott. “His leadership, extensive financial experience and passion for technological innovation will be instrumental as Hyperfine continues to grow and reach more patients through commercial expansion.” Gupta brings over 20 years of experience in the financial and banking industry with a prior background in manufacturing systems and mechanical engineering. He will be responsible for overseeing Hyperfine’s strategic financial initiatives.

Click here to learn more.

Hyperfine, Inc., creator of the first FDA-cleared portable MRI device, and Liminal Sciences, Inc. to be listed on Nasdaq through a business combination with HealthCor Catalio Acquisition Corp.

July 8, 2021

Hyperfine, Inc. (“Hyperfine”), creator of the first U.S. Food and Drug Administration (“FDA”) cleared portable magnetic resonance imaging (“MRI”) device, Swoop™, and Liminal Sciences, Inc. (“Liminal”), a medical device development company dedicated to non-invasive measurement of key vital signs in the brain, today announced their entry into a definitive business combination agreement with HealthCor Catalio Acquisition Corp. (Nasdaq: HCAQ), (“HealthCor Catalio” or the “Company”), a special purpose acquisition company, or SPAC. Upon the closing of the business combination, HealthCor Catalio Acquisition Corp. will be renamed as Hyperfine, Inc., and the combined company’s Class A common stock is expected to be listed on The Nasdaq Stock Market (“Nasdaq”) under ticker symbol “HYPR.”

Click here to learn more.

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

June 15, 2021

Mr. Huennekens is a successful CEO, Chairman, board member, and entrepreneur, having been involved in more than 20 medtech startup, growth, and public companies with market valuations totaling over $20 billion and benefitting over 20 million patients with the therapies and diagnostics they deliver. As Executive Chairman, he will partner with recently announced President and CEO Dave Scott to build Hyperfine into a leading ecosystem in the brain and beyond. This will begin with the continuation of the rapidly expanding commercialization of the world’s first compact portable MRI system (FDA cleared in August 2020) and preparing Hyperfine for future growth and readiness for a public market offering. His prior company and board experience includes recent IPOs at Actus Medical and Envista, Verb Surgical/Google, Volcano, NuVasive, ViewRay, EndoChoice, Digirad and Edwards Lifesciences.

Click here to learn more.

Hyperfine Names Veteran Medical Device and Innovation Leader Dave Scott President and CEO

June 8, 2021

Mr. Scott joins Hyperfine with a 25-year career building and leading high-performing teams at both startups and Fortune 500 companies related to digital surgery, digital health ecosystems, surgical robotics, and medical imaging and diagnostics. He has a passion for disruptive innovations and has built and successfully scaled four startup companies to commercialization. As CEO, Scott will lead the company’s bold strategic growth plans for the rapid commercialization and adoption of the category-defining Swoop™ MR Imaging System.

Click here to learn more.

Hyperfine Raises $90 Million in Oversubscribed Series D Financing

February 10, 2021

Hyperfine has closed an oversubscribed $90 Million Series D financing round, with support from investors including GV (formerly Google Ventures), Nextrans (KClavis-Nextrans), Axiom Associates, Huami, Colle Capital, LSS, and Altium Capital.

Click here to learn more.

Click on the image below to view the investor presentation.

View the investor’s disclaimer.

Hyperfine Investor Contact:
investors@hyperfine.io